Loading...
Home2024-07-23T16:26:50+00:00

ABOUT US

Nanostics is a commercial-stage precision health company developing novel tools to help bring clarity to healthcare decisions.

De-risking prostate cancer screening with ClarityDX Prostate

ClarityDX Prostate builds upon the utility of clinical features and blood-based biomarkers to determine a patient’s risk of having aggressive prostate cancer. This empowers patients and their healthcare providers make more informed healthcare decisions. 

Dr. John Lewis

Dr. John Lewis

CEO of Nanostics and Bird Dogs Chair of Translational Oncology at the University of Alberta

After over a decade of collaboration and innovation, powered by the generosity of so many, Nanostics has developed ClarityDX Prostate, a breakthrough that substantially enhances the prediction of aggressive prostate cancer and reduces the number of prostate biopsies, which are invasive, uncomfortable and carry some risk.

Recent News

2024 PROSTATE CANCER SCREENING UPDATE

Our success is possible thanks to the support of our many Canadian and international collaborators, funders, and partners.

Go to Top